



PRESS RELEASE

PledPharma AB
Stockholm, 30 November 2020

Change in the number of shares and votes in PledPharma

The number of shares and votes in PledPharma AB (publ) (“**PledPharma**” or the “**Company**”) has increased during the month of November due to the acquisition of Rare Thyroid Therapeutics International AB (RTT) with a purchase price consisting of, amongst others, 63,773,345 newly issued shares and after the exercise of the over-allotment option as a consequence of the oversubscribed rights issue. The press releases regarding the directed issue of shares and the over-allotment were published on 5 October, 28 October, 3 November, and 25 November 2020. A total of 73,297,154 shares and votes have been added.

At 30 November 2020, which is the last trading day in November, the number of shares and votes in the Company amounts to 126,830,475.

The shares in the rights issue as the Company announced about on 5 October, 28 October and 25 November 2020 will be registered with the Swedish Companies Registration Office in December 2020.

For further information, please contact:

Nicklas Westerholm, CEO PledPharma
Tel. +46 (0)73 354 20 62
nicklas.westerholm@pledpharma.se

This information is information that PledPharma AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 30 November 2020 at 2:30 pm. CET.

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. Through the acquisition of Rare Thyroid Therapeutics (RTT), the clinical portfolio also includes Emcitate®, for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A pivotal Phase IIb/III early intervention study is planned to start in Q4 2020. Emcitate has been granted Orphan Drug Designation in the US and EU. The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx is warranted via strategic partnerships and is expected to be announced in Q4 2020. The company is planning for a name change to Egetis Therapeutics pending a resolution at the EGM on December 11, 2020

PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <http://www.pledpharma.com/>